Sign up to save your podcasts
Or
Share PDC*line Pharma Raises €20M in Series B Financing
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
PDC*line Pharma Raises €20M in Series B Financing
PDC*line Pharma, a Liege, Belgium and Grenoble, France-based clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, completed its €20m Series B round of financing.
This included €13.9M ($15.5M) from new backers Korean Investment Partners, Shinhan-Cognitive Start-up Fund and UTC 2019 BIOVENTUREFUND, SRIW (The Regional Investment Company of Wallonia) and Sambrinvest (the investment fund of Charleroi), and €6.1M ($6.8M) in loans and subsidies from the Walloon Region of Belgium.
The new investors joined historical backers SFPI-FPIM, the Belgian Federal Holding and Investment Company, Noshaq Group (ex-Meusinvest), the Financière Spin-off Luxembourgeoise/INVESTSUD Group and a group of international business angels and entrepreneurs.
The company intends to use the funds to advance its development efforts.
The total deal is worth €108M ($120M), plus tiered royalties on net sales in Asia. | To read full story, visit https://startuparound.com/read/1579687211.416645/PDC*line-Pharma-Raises-€20M-in-Series-B-Financing?ref=audio_experience
View all episodes
By Startup AroundPDC*line Pharma, a Liege, Belgium and Grenoble, France-based clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, completed its €20m Series B round of financing.
This included €13.9M ($15.5M) from new backers Korean Investment Partners, Shinhan-Cognitive Start-up Fund and UTC 2019 BIOVENTUREFUND, SRIW (The Regional Investment Company of Wallonia) and Sambrinvest (the investment fund of Charleroi), and €6.1M ($6.8M) in loans and subsidies from the Walloon Region of Belgium.
The new investors joined historical backers SFPI-FPIM, the Belgian Federal Holding and Investment Company, Noshaq Group (ex-Meusinvest), the Financière Spin-off Luxembourgeoise/INVESTSUD Group and a group of international business angels and entrepreneurs.
The company intends to use the funds to advance its development efforts.
The total deal is worth €108M ($120M), plus tiered royalties on net sales in Asia. | To read full story, visit https://startuparound.com/read/1579687211.416645/PDC*line-Pharma-Raises-€20M-in-Series-B-Financing?ref=audio_experience